The top repurposed COVID-19 therapeutics are leron

The top repurposed COVID-19 therapeutics are leronlimab manufactured by CytoDyn Inc. (OTCMKTS: CYDY) and CD24Fc manufactured by privately held OncoImmune. Both of these drugs are monoclonal antibodies. Right now leronlimab is best in breed and slated for regulatory approval this year in either the US, UK, Philippines, or the European Union. Leronlimab was the first COVID-19 drug to meet their endpoint in a randomized double blind placebo controlled trial. In their mild to moderate clinical trial CD-10 they had a 60% reduction in SAE’s over placebo. The drug has been dosed in over 1000 patients in over 5 indications. The NEWS2 score identifies patients that risk progressing. In the CD-10 trial there was a statistically significant reduction in the score over placebo (p=.023). In addition their clinical symptom score was 90% in the active arm versus 71% in placebo at day 3. Based on their patient population this was only clinically significant and with a slightly larger trial would be statistically significant. CytoDyn also has an interim readout in the coming weeks for their Severe to Critical COVID-19 patients. They have virtually no exclusion criteria and are going after all cause 28 day mortality as their primary endpoint, the gold standard.


https://reportedtimes.com/emerginggrowth-com-...-makeover/